Nuformix plc (LON:NFX – Get Free Report)’s stock price fell 12% during trading on Wednesday. The company traded as low as GBX 0.11 and last traded at GBX 0.11. Approximately 24,017,961 shares were traded during trading, a decline of 17% from the average session volume of 29,027,189 shares. The stock had previously closed at GBX 0.12.
Nuformix Trading Down 6.1%
The stock has a 50-day moving average price of GBX 0.15 and a two-hundred day moving average price of GBX 0.17. The stock has a market cap of £2.82 million, a price-to-earnings ratio of -3.69 and a beta of 1.53.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.
Recommended Stories
- Five stocks we like better than Nuformix
- 3 Stocks to Watch as Wall Street Wealth Fuels Consumer Spending
- Expecting a Market Correction? This Mega-Cap ETF Deserves a Spot on Your Watchlist
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
